Effect of exjade on level in patients with thalassemia
Phase 2
- Conditions
- major thalassemia.Beta thalassaemia
- Registration Number
- IRCT201412097677N3
- Lead Sponsor
- Vice chancellor for research, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Inclusion Criteria: Approved based on clinical symptoms and history of thalassemia and hemoglobin electrophoresis; full cooperation during the study; treatment with deferoxamine subcutaneous injection and ferritin levels below 3000. Exclusion criteria: Deferiprone gastrointestinal intolerance; leukocytes less than 3,000; severe liver disease; ascites; lack of consent, lack of cooperation in the history of previous treatment regimens (blood transfusion and deferoxamine).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum ferritin level. Timepoint: Before the intervention; three months after the intervention and six months after intervention. Method of measurement: Based on the results of test ferritin.
- Secondary Outcome Measures
Name Time Method